AM Investment Strategies’s Acadia Pharmaceuticals ACAD Stock Holding History

AM Investment Strategies’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-16,100	Closed	-$504K	–	109
2023 Q4	$504K	Sell	16,100 -900	-5%	-$21.5K	0.14%	66
2023 Q3	$354K	Hold	17,000	–	–	0.12%	68
2023 Q2	$407K	Hold	17,000	–	–	0.13%	63
2023 Q1	$320K	Hold	17,000	–	–	0.11%	69
2022 Q4	$271K	Hold	17,000	–	–	0.1%	73
2022 Q3	$278K	Hold	17,000	–	–	0.1%	69
2022 Q2	$240K	Hold	17,000	–	–	0.08%	80
2022 Q1	$412K	Hold	17,000	–	–	0.11%	73
2021 Q4	$397K	Sell	17,000 -200	-1%	-$4.02K	0.1%	81
2021 Q3	$286K	Sell	17,200 -1,400	-8%	-$27K	0.08%	88
2021 Q2	$454K	Buy	18,600 +800	+4%	+$18.1K	0.12%	72
2021 Q1	$459K	Hold	17,800	–	–	0.13%	69
2020 Q4	$952K	Buy	17,800 +700	+4%	+$34.8K	0.29%	42
2020 Q3	$705K	Buy	+17,100	New	+$738K	0.25%	48

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

AM Investment Strategies's ACAD Position: Q1 2024 in Review

AM Investment Strategies sold out of Acadia Pharmaceuticals (ACAD) in Q1 2024, closing a stake of 16,100 shares — an estimated $504K sold.

AM Investment Strategies first reported a position in ACAD in Q3 2020 and held it in 14 quarters. The position peaked at $952K in Q4 2020. 267 funds tracked by Wall St. Rank hold ACAD as of Q1 2024.

AM Investment Strategies reported no remaining Acadia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
AM Investment Strategies sold 16,100 Acadia Pharmaceuticals shares in Q1 2024, an estimated $504K.
AM Investment Strategies first reported a position in Acadia Pharmaceuticals in Q3 2020 and held it in 14 quarters.
AM Investment Strategies's Acadia Pharmaceuticals position peaked at $952K in Q4 2020.
267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2024.

Based on AM Investment Strategies's 13F filing for Q1 2024, filed 2 May 2024.